Losartan
- Generic Name
- Losartan
- Brand Names
- Hyzaar, Cozaar
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN6O
- CAS Number
- 114798-26-4
- Unique Ingredient Identifier
- JMS50MPO89
- Background
Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Los...
- Indication
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hyper...
- Associated Conditions
- Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
- Associated Therapies
- -
VA NEPHRON-D: Diabetes iN Nephropathy Study
- Conditions
- Interventions
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 1448
- Registration Number
- NCT00555217
- Locations
- 🇺🇸
VA Palo Alto Health Care System, Palo Alto, California, United States
🇵🇷VA Medical Center, San Juan, San Juan, Puerto Rico
🇺🇸VA Medical Center, Memphis, Memphis, Tennessee, United States
Losartan Therapy in Pulmonary Hypertension
- Conditions
- Interventions
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Baskent University
- Registration Number
- NCT00519870
LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 201
- Registration Number
- NCT00496834
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- National Human Genome Research Institute (NHGRI)
- Target Recruit Count
- 3
- Registration Number
- NCT00467831
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)
- Conditions
- Interventions
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 40
- Registration Number
- NCT00447603
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
- Conditions
- Interventions
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00446563
- Locations
- 🇩🇪
25 centers in Germany, Ludwigshafen, Germany
Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Carelon Research
- Target Recruit Count
- 608
- Registration Number
- NCT00429364
- Locations
- 🇺🇸
Washington University School of Medicine, St Louis, Missouri, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital, Palo Alto, California, United States
Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 80
- Registration Number
- NCT00419835
- Locations
- 🇧🇷
Nephrology Department, Sao Paulo University Medical School, Sao Paulo, Brazil
Treating the Endothelium to Restore Insulin Sensitivity
- Conditions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2013-09-24
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 17
- Registration Number
- NCT00402194
- Locations
- 🇺🇸
Indiana University Hospital GCRC, Indianapolis, Indiana, United States
Pioglitazone and Losartan Provides Additional Renoprotection
- Conditions
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 60
- Registration Number
- NCT00364988
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.